Overview

* Ventyx Q3 net loss narrows to $22.8 mln from $35.2 mln last year

* Company's cash reserves expected to fund operations into at least H2 2026

* VTX3232 shows promising Phase 2 results for cardiovascular and Parkinson's disease

Outlook

* Company expects topline data from VTX2735 study in Q4 2025

* Ventyx's cash expected to fund operations into at least H2 2026

Result Drivers

* FINANCIAL POSITION - Cash reserves of $192.6 mln expected to fund operations into at least H2 2026

* Expenses - R&D expenses fell to $17.7 mln from $30.6 mln a year ago, while general and administrative costs declined to $7.2 mln from $7.9 mln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.32

Q3 Net -$22.83

Income mln

Q3 $24.87

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Ventyx Biosciences Inc ( VTYX ) is $12.00, about 25% above its November 5 closing price of $9.00

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)